Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

SVB Leerink Maintains Outperform on Aligos Therapeutics, Raises Price Target to $11

SVB Leerink analyst Roanna Ruiz maintains Aligos Therapeutics (NASDAQ:ALGS) with a Outperform and raises the price target from $10 to $11.
byBenzinga Newsdesk
March 11, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

SVB Leerink analyst Roanna Ruiz maintains Aligos Therapeutics (NASDAQ:ALGS) with a Outperform and raises the price target from $10 to $11.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts